Published: 11 April 2024
Author(s): Alba Rodríguez-Muñoz, María José Picón-César, Francisco J. Tinahones, José Ignacio Martínez-Montoro
Issue: May 2024
Section: Review Article

Type 1 diabetes (T1D) is a complex and demanding chronic disease characterized by a severe lack of insulin synthesis which needs to be supplied exogenously [1,2]. In this context, people living with T1D need to follow a lifelong treatment (often starting at early stages of life) based on multiple daily injection insulin therapy (MDI) or continuous subcutaneous insulin infusion, also with a strict monitorization of glucose levels to optimize dosing decisions, which may allow to achieve an optimal glycemic control and prevent chronic complications associated with the disease [1,2].


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.